Cargando...
Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome
BACKGROUND: Tandutinib (MLN 518, Millennium Pharmaceuticals, Cambridge, MA) is an orally active multitargeted tyrosine kinase inhibitor that is currently under evaluation for the treatment of glioblastoma and has been used in the treatment of leukemia. In prior clinical and animal studies, a dose-de...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Lippincott Williams & Wilkins
2011
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3034397/ https://ncbi.nlm.nih.gov/pubmed/21242491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3182074a69 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|